EUVIMEDAtrasti EUVIMED
Multizentrische Studie

Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients

Vaisak O Nair iD, Zachary A Yetmar iD, Bismarck S Bisono-Garcia iD, Lisa Brumble iD, Holenarasipur R Vikram iD, Raymund R Razonable iD, Elena Beam iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70342 ↗

At a glance

Multizentrische Studie in Clinical Transplantation, 2025. Written by Vaisak O Nair and 6 co-authors. Institution: Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Cytomegalovirus Infections, Heart Transplantation, Transplant Recipients, Graft Rejection. 34 references. Funded by: National Center for Advancing Translational Sciences (NCATS).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Purpose

The purpose of this study was to evaluate the incidence and risk factors for developing recurrent clinically significant cytomegalovirus infections (csCMVi) in heart transplant recipients.

Methods

We conducted a retrospective cohort study involving adult heart transplant recipients at three large transplant centers in the United States between January 2011 and March 2019. All patients with a history of csCMVi, defined as CMV disease or CMV infection requiring preemptive therapy, were followed from the date of treatment completion for the primary csCMVi episode. Outcomes of interest were recurrent csCMVi and all‐cause mortality.

Results

Among 98 heart transplant recipients with csCMVi, 22 (22.4%) episodes of recurrent csCMVi occurred. Median time‐to‐recurrent csCMVi was 31.5 (IQR 21.3–59.8) days following treatment completion. A preceding episode of CMV disease (versus infection) was associated with a lower risk of recurrent csCMVi (HR 0.29, 95% CI 0.08–0.98; p = 0.047). Patients with lymphopenia had higher rates of recurrent csCMVi without statistical significance (HR 2.13, 95% CI 0.88–5.13; p = 0.093). Seroconversion by the end‐of‐therapy among CMV D+/R− mismatched patients was associated with a reduced risk of csCMVi recurrence (HR 0.07, 95% CI 0.02–0.30; p < 0.001). Overall, 17 (17.3%) patients died during follow‐up, which was not significantly higher among those with recurrent csCMVi (HR 2.13, 95% CI 0.78–5.79; p = 0.141).

Conclusions

About one in five heart recipients with csCMVi developed post‐treatment recurrence. A preceding episode of CMV disease and seroconversion was protective against recurrence. Lymphopenia may be a practical biomarker to stratify recurrence risk. Overall, recurrent csCMVi was not significantly associated with mortality.

Subjects

MeSH terms (MEDLINE)

Cytomegalovirus InfectionsHeart TransplantationTransplant RecipientsGraft RejectionCytomegalovirusPostoperative ComplicationsHumansFemaleMaleRetrospective StudiesRisk FactorsMiddle AgedFollow-Up StudiesPrognosisRecurrenceIncidenceAdultSurvival RateGraft Survival

Author keywords

cytomegalovirusheart transplantationincidencemortalityrecurrenceseroconversion

Authors and institutions

  • Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Infectious Diseases and Transplant Center, Mayo Clinic, Phoenix, Arizona, USA.

ORCID profiles: Vaisak O Nair, Zachary A Yetmar, Bismarck S Bisono-Garcia, Lisa Brumble, Holenarasipur R Vikram, Raymund R Razonable, Elena Beam

Funding

  • National Center for Advancing Translational Sciences (NCATS)

Cite

APA

Nair, V. O., Yetmar, Z. A., Bisono-Garcia, B. S., Brumble, L., Vikram, H. R., Razonable, R. R., & Beam, E. (2025). Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70342

Vancouver

Nair VO, Yetmar ZA, Bisono-Garcia BS, Brumble L, Vikram HR, Razonable RR, et al. Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70342

BibTeX
@article{Nair2025,
  author = {Nair, Vaisak O and Yetmar, Zachary A and Bisono-Garcia, Bismarck S and Brumble, Lisa and Vikram, Holenarasipur R and Razonable, Raymund R and Beam, Elena},
  title = {Risk Factors and Outcomes of Recurrent Cytomegalovirus Infection in Heart Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70342}
}
Start for free →